CHARLES WYKOFF to Macular Degeneration
This is a "connection" page, showing publications CHARLES WYKOFF has written about Macular Degeneration.
Connection Strength
9.094
-
Treatment of geographic atrophy: an update on data related to pegcetacoplan. Curr Opin Ophthalmol. 2024 Jan 01; 35(1):64-72.
Score: 0.763
-
Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise. Ophthalmic Surg Lasers Imaging Retina. 2023 10; 54(10):589-598.
Score: 0.761
-
Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmol. 2022 12; 7(1).
Score: 0.721
-
Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 03; 235:131-142.
Score: 0.660
-
Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration. BioDrugs. 2021 May; 35(3):303-323.
Score: 0.643
-
Reply. Ophthalmol Retina. 2021 01; 5(1):e1-e2.
Score: 0.629
-
Re: Adrean et?al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053). Ophthalmology. 2019 03; 126(3):e18-e19.
Score: 0.554
-
Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. J Manag Care Spec Pharm. 2018 Feb; 24(2-a Suppl):S3-S15.
Score: 0.514
-
Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018 04; 102(4):460-464.
Score: 0.497
-
Quantitative comparison of inner and outer retinal intraretinal hyperreflective foci in age-related macular degeneration. Exp Eye Res. 2025 Jul; 256:110415.
Score: 0.212
-
Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy. Can J Ophthalmol. 2025 Apr; 60(2):91-99.
Score: 0.202
-
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023 10 21; 402(10411):1434-1448.
Score: 0.191
-
RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. Retina. 2023 07 01; 43(7):1051-1063.
Score: 0.186
-
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS? Registry. Ophthalmology. 2023 09; 130(9):937-946.
Score: 0.185
-
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 12; 37(17):3551-3557.
Score: 0.184
-
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul; 130(7):735-747.
Score: 0.183
-
Optical Coherence Tomography Biomarkers for Conversion to Exudative Neovascular Age-related Macular Degeneration. Am J Ophthalmol. 2023 03; 247:137-144.
Score: 0.178
-
OCT Risk Factors for Development of Atrophy in Eyes with Intermediate Age-Related Macular Degeneration. Ophthalmol Retina. 2023 03; 7(3):253-260.
Score: 0.178
-
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 09; 129(9):974-985.
Score: 0.173
-
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol. 2022 Jan 01; 140(1):20-28.
Score: 0.169
-
Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid. Ophthalmol Retina. 2022 05; 6(5):377-386.
Score: 0.168
-
Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study. Ophthalmol Retina. 2022 03; 6(3):219-227.
Score: 0.163
-
Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021 May 01; 139(5):542-547.
Score: 0.161
-
Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 09; 20(9):999-1008.
Score: 0.152
-
Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. Ophthalmology. 2020 06; 127(6):769-783.
Score: 0.146
-
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.
Score: 0.142
-
Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad. Am J Ophthalmol. 2016 09; 169:xiv-xvi.
Score: 0.116
-
ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics. Retina. 2016 Jul; 36(7):1349-56.
Score: 0.115
-
Risk factors for development of hyper-reflective foci overlying drusen in eyes with intermediate age-related macular degeneration. Br J Ophthalmol. 2024 Aug 22; 108(9):1234-1239.
Score: 0.051
-
Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration: A Cross Sectional Study. Ophthalmol Retina. 2024 Sep; 8(9):854-862.
Score: 0.049
-
The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis. Surv Ophthalmol. 2024 May-Jun; 69(3):349-361.
Score: 0.048